← Eichor
Condition: Newly Diagnosed Acute Myeloid Leukemia Aml Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Newly Diagnosed Acute Myeloid Leukemia Aml

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML
NA · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06232694Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06511882VA vs DA for Newly Diagnosed Hig-risk AML
Phase 2/Phase 3 · 2 location(s) · The First Affiliated Hospital of Soochow University · NCT05939180Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07490288APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
Phase 1 · 7 location(s) · Aptevo Therapeutics · NCT06634394Cardioprotection in AML
Phase 2 · 1 location(s) · University of Virginia · NCT04977180Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML
Phase 2 · 1 location(s) · Beijing 302 Hospital · NCT07078591Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Pat
Phase 3 · 43 location(s) · Stichting Hemato-Oncologie voor Volwassenen Nederland · NCT07223814Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Ne
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06532552DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML
Phase 3 · 1 location(s) · The Second Affiliated Hospital of Kunming Medical University · NCT07712848Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML
Phase 2 · 2 location(s) · The First Affiliated Hospital of Soochow University · NCT06429098HVA vs IA/DA or VA in the Treatment of ND HR-AML
Phase 3 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT06810791Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment
Phase 2 · 2 location(s) · OHSU Knight Cancer Institute · NCT06504459Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Trea
Phase 2 · 227 location(s) · National Cancer Institute (NCI) · NCT06317649Relation Between Venetoclax Plasma Concentration and Remission in Adults with Acute Myeloid Leukemia (PREDICLAX)
Phase N/A · 1 location(s) · University Hospital, Caen · NCT06045819MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
Phase 3 · 11 location(s) · Zhongnan Hospital · NCT06345365Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Phase 3 · 106 location(s) · Kura Oncology, Inc. · NCT07007312A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML
Phase 1/Phase 2 · 1 location(s) · Sunshine Lake Pharma Co., Ltd. · NCT05133882A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia
Phase 1/Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07028073a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07007949Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-
Phase 3 · 91 location(s) · University of Ulm · NCT04628026Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Phase 1 · 2 location(s) · OHSU Knight Cancer Institute · NCT04659616A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax,
Phase 1 · 44 location(s) · Kura Oncology, Inc. · NCT05735184Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06621199Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML
NA · 1 location(s) · Yang Xiaotian · NCT06536010Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM
Phase 3 · 83 location(s) · Syndax Pharmaceuticals · NCT07211958Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
Phase 2/Phase 3 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT05805098Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
Phase N/A · 2 location(s) · Wake Forest University Health Sciences · NCT06580106ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute My
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05010122PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed A
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT02390635
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.